Flora Fertility has raised US$5m in seed funding to roll out fertility insurance across the US, with plans to expand into Canada.

The round was led by ManchesterStory, with participation from Slauson & Co., TruStage Ventures, BDC Capital, Marathon Fund, Adara Venture Capital and strategic angel investors. Existing investors include Highline Beta, Everywhere Ventures and Cartography Capital.

Laura McDonald, co-founder of Flora Fertility, said: “Fertility is one of the largest uninsured financial risks people face, yet the system today only offers support once you’re already in crisis and often only if your employer provides it.

“We’re creating a new category where fertility becomes something you can proactively plan for, not just pay for when it’s too late.”

Flora says it is introducing a new InsurTech category with individually owned, portable fertility insurance designed to address a gap in healthcare cover.

The company says it wants to shift fertility from a reactive expense to a proactive, data-driven financial planning tool, using AI, personalised underwriting and risk modelling.

The platform lets people buy coverage without relying on an employer, helping it continue through job changes and different stages of life.

Flora’s policies cover a full range of fertility treatments, including diagnostics, medications, intrauterine insemination and in vitro fertilisation, with entry-level pricing starting at about US$20 a month.

The company estimates that infertility affects one in six people globally, while treatment costs can range from US$30,000 to US$50,000, leaving the vast majority of patients without access to care.

Flora says its platform currently reaches more than 10 million prospective policyholders across North America.

The funding will be used to expand Flora’s underwriting capabilities, scale distribution and further develop its platform as it seeks to establish a new market within women’s health and insurance.

Nicole Gunderson, partner at ManchesterStory, said: “Flora is building something that has never existed before, affordable, portable fertility insurance that meets the next generation of women exactly where they are.

“The InsurTech opportunity here is enormous, and the Flora team has the expertise, technology, and vision to define this category.”

Dr Christy Lane, co-founder of Flora Fertility, added: “Fertility has always been treated as unpredictable and uninsurable, but the data tells a different story.

“The earlier someone can access that coverage, the better their outcomes and the lower their costs, which is what makes this model so powerful.

“We’re turning fertility from a reactive medical expense into a proactive, data-driven financial decision.”

By Women’s Health Week

When the New York Stock Exchange signs on as the Official Exchange Partner of a women’s health event, it’s worth paying attention to.

Women’s Health Week USA, taking place May 13-14 at the New York Academy of Medicine in New York City, has confirmed the NYSE as its Official Exchange Partner for 2026.

It is one of the most significant institutional endorsements the women’s health sector has seen, and it says something meaningful about where global capital markets are directing their attention.

Find out more about WHW USA 2026 here.

What the Partnership Involves

This is not simply a logo on a lanyard.

The NYSE partnership comes with a set of activations that put women’s health in front of audiences well beyond the event itself.

On the morning of May 13, Women’s Health Week will be featured in the NYSE Market Update, reaching an audience of approximately 200 million viewers across outlets including Yahoo Finance and the Financial Times.

For a sector that has historically struggled for mainstream financial visibility, that kind of reach is significant.

Women’s Health Week will also light up the North Star Billboard in Times Square for a full week around the event, placing the brand at the centre of one of the most commercially visible locations in the world.

NYSE will produce live and taped interviews with WHW leadership and keynote speakers, distributed across NYSE Live, Taking Stock, and partner platforms reaching tens of millions of viewers monthly.

A dedicated NYSE content team will be on the ground at the New York Academy of Medicine capturing the conversations and connections taking place across both days.

The NYSE’s Healthcare & Life Sciences team will also take to the stage at Women’s Health Week USA, sharing their perspective on trends shaping the sector from a capital markets standpoint.

Why It Matters

The partnership is a signal as much as it is a sponsorship.

Women’s health has spent years making the case that it is a commercially serious category.

The NYSE’s involvement makes that case in a language the broader financial world understands.

Women’s Health Week USA 2026 is themed around The Era of Scale, a deliberate framing around the idea that the sector has moved beyond early validation into the harder work of institutionalisation.

Capital is moving. M&A activity is increasing. Generalist investors are entering a space that was once left to specialists. The NYSE partnership fits neatly into that narrative.

With 600+ senior decision makers confirmed across investors, founders, multinationals, payers and policymakers, the event is already one of the most commercially concentrated gatherings in the women’s health calendar.

The NYSE’s reach extends that concentration well beyond the walls of the New York Academy of Medicine.

Find out for yourself why this partnership is so perfect and join Women’s Health Week USA. Secure your ticket here.

The Pitch Sessions

For founders and early-stage companies, Women’s Health Week USA also hosts a mainstage Pitch Session across two categories: Medical Devices & Therapeutics and Consumer & Tech. Fifteen companies will be selected to pitch in front of the full audience.

Applications close April 10.

They are free to submit, and any company working on a condition that affects women exclusively, differently, or disproportionately is eligible.

Apply to pitch

View the full programme

Women’s HealthX is convening a powerful lineup of pharmaceutical and biotech leaders, uniting global organisations including AstraZeneca, Bayer, Gilead, Chiesi, Eli Lilly, Alexion, and Daré Bioscience alongside 750+ senior clinicians, hospital leaders, insurers, and policy makers shaping the future of women’s health.

As the women’s health market continues to evolve, the event provides a unique platform for pharma leaders to share how they are leveraging clinical trial data, real world evidence, and digital innovation to reduce regulatory risk, improve representation in research, and unlock new opportunities for partnership and pipeline growth.

Across seven dedicated stages covering the full lifecycle of care, attendees will gain direct insight into how industry leaders are driving measurable change in outcomes, access, and equity.

Confirmed sessions and trailblazers include:

Maternity & Maternal Care

• Empowering Mothers, Advancing Equity, and Improving Outcomes in Premature Care

Erica Smith, Vice President, Value & Market Access, US, Chiesi

Evidence, Data & Innovation

• Addressing Design Barriers: Paving the Way for Sex Specific Data Clarity

Julieta Jimenez, Executive Director, Program Management Clinical Operations, V&I, AstraZeneca

• Design Trials That Generate Clinically Meaningful Evidence for Women

Luba Soskin, Global Clinical Lead, Women’s Health, Bayer

Chronic Disease Management

• Improving Outcomes in Obesity Through Evidence Based Person Centred Care

Tracy Sims, Executive Director, Corporate Affairs, Cardiometabolic Health, Eli Lilly

• Tackling Sex Based Health Inequities by Breaking Down Barriers and Bias

Adrian Kielhorn, Senior Director, Global Head HEOR Neurology, Alexion

Sexual Health & Wellness

• The Clinical Impact of Internal Stigma in Sexual Health

Kesha O’Reilly, Director Medical Affairs, HIV Franchise, Gilead

• Explore Innovative Product Manufacturing Pathways Beyond Conventional Regulatory Models

David Friend, Chief Science Officer, Daré Bioscience

We have also just announced Endometriosis Advocate Padma Lakshmi as a keynote speaker, bringing one of the most influential voices in women’s health advocacy to the stage.

See full list of confirmed trailblazers here

Together, these leaders represent the organisations driving innovation across research, development, and commercialisation, offering practical insight into how to bring safer, more effective solutions to women worldwide.

The program moves beyond discussion into delivery, equipping attendees with the latest clinical evidence, regulatory strategies, and innovation frameworks needed to accelerate impact across the healthcare ecosystem.

With senior decision makers from across pharma, biotech, and healthcare in attendance, women’s healthX is where partnerships are formed, strategies are shaped, and the future of women’s health is defined.

Secure your free place now